Ultrasound Contrast Agents Market Analysis

The ultrasound contrast agents market is segmented on the basis of therapeutic areas into cardiovascular diseases, renal associated diseases, and others. The cardiovascular disease segment is expected to witness a significant growth by the end of 2030 on the back of the increasing incidence of cardiovascular diseases globally, backed by unhealthy lifestyle of the masses. According to WHO, 17.9 million people died from cardiovascular diseases in 2019, which accounted for 32% of all global deaths. These diseases are more prevalent in men as compared to women. On the basis of application, the molecular imaging segment in the global ultrasound contrast agents market is expected to grow with a significant CAGR over the forecast period. The growth of the segment can be attributed to the growing requirement for ultrasound contrast agents for various ultrasound-based molecular diagnostic procedures and screenings.

Our in-depth analysis of the global market includes the following segments:

Therapeutic Area

Instruments
Consumables & Reagents

Application

Molecular Imaging
Gene Therapy
Drug Delivery
Stem Cell Delivery

End-user

Hospital
Diagnostic Centers
Ambulatory Surgical Centers
Others

Frequently Asked Questions (FAQ)

Ultrasound Contrast Agents Market size is set to expand at over 19.8% CAGR during the forecast period i.e., between 2024-2036.

Rising prevalence of chronic disorders and increasing implementation of ultrasound diagnosis will fuel the market growth.

Asia Pacific is predicted to dominate majority revenue share by 2036, owing to increasing necessity for advanced diagnosis methods to detect various disease indications such as neurological disorders, cancer, cardiovascular diseases, and others.

The major players in the market include Bristol-Myers Squibb, GE Healthcare, Lantheus Holdings, Inc., Bracco Diagnostic Inc., Siemens Healthcare GmbH, and others.

Ultrasound Contrast Agents Market Analysis